x

This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 




Actavis eyes $100 million after OxyContin settlement

29-04-2013

Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.


actavis, oxycontin, purdue pharma, Fitzpatrick, Cella, Harper & Scinto

LSIPR

Payment types accepted